Revolution Medicines' Rasonque Launch Seen as Rapid, RBC Says

MT newswire2026/08/27 15:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

11:24 AM EDT, 08/27/2026 (MT Newswires) -- Revolution Medicines' (RVMD) Rasonque tablets for the treatment of metastatic pancreatic cancer could see a "rapid launch," driven by patient and physician interest amid a lack of alternative therapies, RBC Capital Markets said in a Wednesday note. The drug's pricing of $39,800 for a 30-day supply was above RBC's expectations, while payer friction is expected to be minimal, the brokerage said. RBC also expects Rasonque's "aggressive" adoption given its positive data and high awareness among doctors and patients, among others. RBC projects strong Rasonque revenue in Q3 and Q4, estimating $249 million in US sales in 2026, according to the note. The investment firm also said the drug's label language could provide flexibility for some patients to receive Rasonque in the frontline setting, despite the lack of a formal first-line approval. RBC raised its price target on Revolution Medicines to $251 from $203, with an outperform rating. Price: 218.34, Change: +2.90, Percent Change: +1.35

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The latest forecast from the IMF shows that global public debt will exceed 100% of GDP by 2029, two years earlier than previously expected. The IMF Managing Director issued a rare warning, specifically naming the United States’ debt path as “unsustainable” and pointing out that fiscal consolidation in various countries is seriously lagging. What's even more dangerous is that persistent inflation may force the Federal Reserve to continue raising interest rates, increasing financing costs and creating a vicious cycle of "high debt—high interest rates—even higher debt."

华尔街见闻•2026/09/21 06:51